WO2026139021 - ANTI-PD-L1 AND 4-1BB BISPECIFIC ANTIBODY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/139021
Publication Date
02.07.2026
International Application No.
PCT/CN2025/145934
International Filing Date
26.12.2025
Title **
[English]
ANTI-PD-L1 AND 4-1BB BISPECIFIC ANTIBODY AND USE THEREOF
[French]
ANTICORPS BISPÉCIFIQUE ANTI-PD-L1 ET 4-1BB ET SON UTILISATION
[Chinese]
抗PD-L1和4-1BB双特异性抗体及其应用
Applicants **
BIO-THERA SOLUTIONS, LTD.
Inventors
LIU, Guosheng
CHEN, Caiyan
HUANG, Xianming
Priority Data
202411945766.7
27.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3128 | |
| EPO | Filing, Examination, Granting | 40916 | |
| Japan | Filing, Examination, Granting | 3572 | |
| South Korea | Filing, Examination, Granting | 5116 | |
| USA | Filing, Examination, Granting | 18340 |
Total:
71,072
Contact Us
Abstract[English]
The present invention belongs to the field of biomedicine. Provided are a bispecific antibody and the use thereof. The bispecific antibody contains a first antigen-binding domain targeting PD-L1 and a second antigen-binding domain targeting 4-1BB. The antibody retains the activity of an anti-PD-L1 antibody, achieves a balance between activity and safety, and has an excellent druggability potential.[French]
La présente invention se rapporte au domaine de la biomédecine. L'invention concerne un anticorps bispécifique et son utilisation. L'anticorps bispécifique contient un premier domaine de liaison à l'antigène ciblant PD-L1 et un second domaine de liaison à l'antigène ciblant 4-1BB. L'anticorps conserve l'activité d'un anticorps anti-PD-L1, atteint un équilibre entre l'activité et la sécurité, et a un excellent potentiel de pharmacopotentialité.[Chinese]
属于生物医药领域，提供双特异性抗体及其应用，所述双特异性抗体包含靶向PD-L1的第一抗原结合域和靶向4-1BB的第二抗原结合域。抗体保留了抗PD-L1抗体的活性，实现活性和安全性的平衡，具有非常优良的成药潜力。